In cervical carcinoma, the majority of chemotherapies, radiotherapies, and combinations of chemo- and radiotherapies activate the NF-κB signaling pathway, which results in abnormally increased NF-κB expressionand, in turn, promotes the development of refractory disease [14]. Here, NFKB1 is linked to cervical carcinoma.